Naoya Kato

Correction: Corrigendum: MicroRNA122 is a key regulator of α-fetoprotein expression and influences the aggressiveness of hepatocellular carcinoma

Kentaro Kojima, Akemi Takata, Charles Vadnais et al. · Nature Communications · 2012 · 1.3K citations · Full text

Hepatology, Key Regulator, Epigenetic Regulation +14

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Stephen A. Harrison, Vincent Wai‐Sun Wong, Takeshi Okanoue et al. · Journal of Hepatology · 2020 · 438 citations

Fibrosis, Hepatology, Liver Physiology +9

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

B. Sangro, Stephen L. Chan, Robin Kate Kelley et al. · Annals of Oncology · 2024 · 254 citations · Full text

Interleukin-1β gene polymorphisms associated with hepatocellular carcinoma in hepatitis C virus infection

Yue Wang, Naoya Kato, Yujin Hoshida et al. · Hepatology · 2003 · 168 citations · Full text

Detection of hepatitis C virus ribonucleic acid in the serum by amplification with polymerase chain reaction.

Naoya Kato, Osamu Yokosuka, Masao Omata et al. · Journal of Clinical Investigation · 1990 · 157 citations · Full text

Healthy Subjects, Viral Diagnostics, Hepatitis C Virus +18